We are live on ! Find out more

OmniAb

OABI

Market cap $630M

4.33 USD

-0.42

8.84%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

4.37

+0.04

0.92%

1 day

-8.84%

5 days

-2.48%

1 month

116.5%

3 months

62.78%

6 months

139.23%

Year to date

130.32%

1 year

170.63%

5 years

-55.64%

10 years

-55.64%

About: OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Employees: 89

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 80%

Negative 0%

OmniAb to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management's participation in the following upcoming investor conferences: Nasdaq/LD Micro Summit Series Date: Wednesday, September 9, 2026 H.C. Wainwright 28th Annual Global Investment Conference Date: Tuesday, September 15, 2026 The Nasdaq/LD Micro Summit will take place at the Nasdaq Headquarters in.

OmniAb to Participate in Upcoming Investor Conferences

OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech

OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI's technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M.

OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech

OmniAb Raises 2026 Financial Guidance

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlook,” stated Matt Foehr, Chief Executive Officer of Om.

OmniAb Raises 2026 Financial Guidance

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb's technology platform and expertise in ion channel discovery and screening. “We are pleased to enter into this important new relationship with Lilly,” said M.

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript

OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript

OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript

OmniAb Q2 Earnings Call Highlights

OmniAb NASDAQ: OABI reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and year-end cash outlook.

OmniAb Q2 Earnings Call Highlights

Zacks Investment Research

OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.15 per share a year ago.

OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates

OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and six months ended June 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance. “We are pleased to report a strong quarter and to increase our revenue and cash outlook for 2026 based on continued momentum in our business. Recent u.

OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights

OmniAb to Report Second Quarter 2026 Financial Results on August 6

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on Thursday, August 6, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast What: OmniAb conference.

OmniAb to Report Second Quarter 2026 Financial Results on August 6

OmniAb Names Amechi Nwachuku Chief Operating Officer

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb's proprietary, innovative high-throu.

OmniAb Names Amechi Nwachuku Chief Operating Officer

See News Rankings

Price charts implemented using Lightweight Charts™